Ilumina buys consulting firm

Ilumina (NASDAQ:ILMN) acquires Myraqa, a regulatory and quality consulting form specializing in in vitro diagnostics, especially companion diagnostics. Myraqa's expertise is regulatory strategy and application support, including PMAs, pre-submissions, IDEs, 510(k)s and EU technical files. The acquisition beefs up Ilumina's in-house regulatory capabilities.

Myraqa CEO Mya Thomae will report to Ilumina CMO Rick Klausner, M.D.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs